Clinical Trial Update: Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib plus chemotherapy in TKI-resistant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation | Phase 2 | Status: UNKNOWN